BACKGROUND: Vasoactive drug alprostadil improves microcirculation and can be effective in treating disorders of peripheral nerves. Vascular endothelial growth factor (VEGF) has been shown to have protective action in cerebral ischemia, disorders of spinal cord, and also peripheral nerves. However, the mechanism of action of VEGF in peripheral nerve injuries is uncertain. OBJECTIVES: To study the effect of application of alprostadil on the pathological and functional repair of crush nerve injuries and also the expression of VEGF. MATERIALS AND METHODS: Rat sciatic nerves were crushed by pincers to establish the model of crush injury. All of the 400 sprague dawley (SD) rats were randomly divided into: Control; saline; saline+VEGF-antibody; alprostadil; and alprostadil+VEGF antibody groups. The SPSS 11.5 software was used for statistical analysis. The expression of VEGF in dorsal root ganglia (DRGs), following crush injury to sciatic nerves, was studied by reverse transcribed-polymerase chain reaction (RT-PCR), immunohistochemistry, electromicroscope, and electrophysiology. The effects of alprostadil on expression of VEGF, repair of neural pathology, and recovery of neural function were also evaluated. RESULTS: We found that VEGF messenger ribonucleic acid (mRNA) was significantly increased in alprostadil and alprostadil+VEGF-antibody groups, compared to the saline and saline+VEGF antibody groups. The number of VEGF-positive neurons was significantly increased in the alprostadil group, compared to the saline, saline+VEGF antibody, and alprostadil+VEGF antibody groups. Besides, addition of this drug also caused less pathological changes in DRGs, better improvement of nerve conduction velocities of sciatic nerves, and more increase of toe spaces of right hind limbs of rats. CONCLUSIONS: The vasoactive agent alprostadil may reduce the pathological lesion of peripheral nerves and improve the rehabilitation of the neural function, which may relate to upregulation of the expression of VEGF, following crush injury to the peripheral nerves.
BACKGROUND: Vasoactive drug alprostadil improves microcirculation and can be effective in treating disorders of peripheral nerves. Vascular endothelial growth factor (VEGF) has been shown to have protective action in cerebral ischemia, disorders of spinal cord, and also peripheral nerves. However, the mechanism of action of VEGF in peripheral nerve injuries is uncertain. OBJECTIVES: To study the effect of application of alprostadil on the pathological and functional repair of crush nerve injuries and also the expression of VEGF. MATERIALS AND METHODS:Rat sciatic nerves were crushed by pincers to establish the model of crush injury. All of the 400 sprague dawley (SD) rats were randomly divided into: Control; saline; saline+VEGF-antibody; alprostadil; and alprostadil+VEGF antibody groups. The SPSS 11.5 software was used for statistical analysis. The expression of VEGF in dorsal root ganglia (DRGs), following crush injury to sciatic nerves, was studied by reverse transcribed-polymerase chain reaction (RT-PCR), immunohistochemistry, electromicroscope, and electrophysiology. The effects of alprostadil on expression of VEGF, repair of neural pathology, and recovery of neural function were also evaluated. RESULTS: We found that VEGF messenger ribonucleic acid (mRNA) was significantly increased in alprostadil and alprostadil+VEGF-antibody groups, compared to the saline and saline+VEGF antibody groups. The number of VEGF-positive neurons was significantly increased in the alprostadil group, compared to the saline, saline+VEGF antibody, and alprostadil+VEGF antibody groups. Besides, addition of this drug also caused less pathological changes in DRGs, better improvement of nerve conduction velocities of sciatic nerves, and more increase of toe spaces of right hind limbs of rats. CONCLUSIONS: The vasoactive agent alprostadil may reduce the pathological lesion of peripheral nerves and improve the rehabilitation of the neural function, which may relate to upregulation of the expression of VEGF, following crush injury to the peripheral nerves.
Authors: Ying Wang; Yue Teng Wei; Zhao Hui Zu; Rong Kai Ju; Mu Yao Guo; Xiu Mei Wang; Qun Yuan Xu; Fu Zhai Cui Journal: Pharm Res Date: 2011-05-04 Impact factor: 4.200
Authors: Carlos Rodrigo Camara-Lemarroy; Emmanuel Irineo Gonzalez-Moreno; Francisco Javier Guzman-de la Garza; Nancy Esthela Fernandez-Garza Journal: ScientificWorldJournal Date: 2012-09-10
Authors: Victor Tulio Ribeiro-Resende; Alvaro Carrier-Ruiz; Robertha M R Lemes; Ricardo A M Reis; Rosalia Mendez-Otero Journal: Mol Neurodegener Date: 2012-07-13 Impact factor: 14.195
Authors: Nicholas Beazley-Long; Catherine Elizabeth Moss; William Robert Ashby; Samuel Marcus Bestall; Fatimah Almahasneh; Alexandra Margaret Durrant; Andrew Vaughan Benest; Zoe Blackley; Kurt Ballmer-Hofer; Masanori Hirashima; Richard Phillip Hulse; David Owen Bates; Lucy Frances Donaldson Journal: Brain Behav Immun Date: 2018-03-14 Impact factor: 7.217